Sequencing Therapy for HER2-Positive Metastatic Breast Cancer: Emerging Strategies

Since the initial approval of trastuzumab (Herceptin) in 1998, the armamentarium for HER2-positive (HER2+) metastatic breast cancer has expanded substantially to include lapatinib (Tykerb), pertuzumab (Perjeta), trastuzumab emtansine (T-DM1; Kadcyla), the subcutaneous pertuzumab-trastuzumab fixed-dose combination (Phesgo), tucatinib (Tukysa), and trastuzumab deruxtecan (T-DXd; Enhertu). Most recently, T-DXd in combination with pertuzumab received regulatory consideration in 2025, reflecting a paradigm shift toward moving antibody–drug conjugate (ADC)-based therapy earlier in the treatment course. In a presentation during the Miami Breast Cancer Conference held March 5 to 8, 2026, Giuseppe Curigliano, MD, PhD, University of Milano and Istituto Europeo di Oncologia, Milan, Italy, discussed the challenges of sequencing with all of the options currently available to patients.¹

First-Line Treatment: Current Recommendations

Current ESMO guidelines recommend taxane plus trastuzumab-pertuzumab as the standard first-line regimen for both hormone receptor–positive (HR+) and HR-negative (–), HER2+ metastatic breast cancer, followed by trastuzumab-pertuzumab maintenance.² The phase 3 CLEOPATRA trial (NCT00567190) established this approach, demonstrating a statistically significant progression-free survival (PFS) benefit (median 18.5 vs 12.4 months; HR, 0.62; 95% CI, 0.51-0.75; P <.001) and a meaningful overall survival (OS) advantage (median 57.1 vs 40.8 months; HR, 0.69; 95% CI, 0.58-0.82) compared with placebo plus trastuzumab and docetaxel after nearly 100 months of follow-up.³

The PERUSE single-arm study (NCT01572038) confirmed that the safety and efficacy of pertuzumab plus trastuzumab are maintained regardless of the investigator-selected taxane backbone—docetaxel, paclitaxel, or nab-paclitaxel—yielding a median PFS of 20.7 months and a median OS of 65.3 months.⁴ For patients with HR+/HER2+ metastatic breast cancer who are candidates for chemotherapy-free induction, the PERTAIN study (NCT01491737) demonstrated that adding pertuzumab to trastuzumab plus an aromatase inhibitor improved PFS (median 20.6 vs 15.8 months; HR, 0.67; 95% CI, 0.50-0.89; P =.006), without a significant OS benefit.⁵

Second-Line Treatment: T-DXd vs T-DM1

In the second-line setting, T-DXd has supplanted T-DM1 as the preferred therapy following the landmark DESTINY-Breast03 (NCT03529110) trial.⁶ At a median follow-up of approximately 28 months, T-DXd demonstrated superior PFS compared with T-DM1 (median 28.8 vs 6.8 months; HR, 0.33; 95% CI, 0.26-0.43; P <.0001) and a clinically meaningful OS benefit (median 52.6 vs 42.7 months; HR, 0.73; 95% CI, 0.56-0.94) at a median follow-up of 43 months.⁷ The most clinically relevant adverse event of special interest with T-DXd was interstitial lung disease/pneumonitis, which occurred in 16.7% of patients vs 3.4% with T-DM1. For patients with active brain metastases who are not candidates for immediate local intervention, tucatinib combined with capecitabine and trastuzumab remains an evidence-based alternative.

T-DXd in the First-Line Setting: DESTINY-Breast07 and DESTINY-Breast09

The phase 1b/2 DESTINY-Breast07 trial (NCT04538742) evaluated T-DXd monotherapy (n = 75) and T-DXd plus pertuzumab (T-DXd+P; n = 50) as first-line therapy for HER2+ metastatic breast cancer.⁸ At a median follow-up of approximately 31 to 33 months (data cutoff August 2024), confirmed objective response rates (ORR) were 77.3% and 84.0%, respectively, with median PFS not yet reached. PFS rates at 12 and 18 months were 82.6% and 78.2% for T-DXd monotherapy and 87.5% and 78.8% for T-DXd+P. Efficacy was consistent irrespective of stromal tumor-infiltrating lymphocyte levels, and the safety profile was consistent with prior experience for each agent individually.

These encouraging data formed the rationale for the phase 3 DESTINY-Breast09 (NCT04784715) trial, which randomized 1157 patients with treatment-naive HER2+ metastatic breast cancer 1:1:1 to T-DXd plus placebo, T-DXd+P, or the standard taxane plus trastuzumab-pertuzumab (THP) regimen.⁹ At the prespecified interim analysis (data cutoff February 2025), T-DXd+P demonstrated a statistically significant and clinically meaningful improvement in PFS by blinded independent central review compared with THP (median 40.7 vs 26.9 months; HR, 0.56; 95% CI, 0.44-0.71; P <.00001). A consistent PFS benefit was observed across all prespecified subgroups, including de novo vs recurrent disease, HR+ vs HR– status, and PIK3CA-mutated vs wild-type tumors. Complete response rates were substantially higher with T-DXd+P (13.7%-16.5%) than with THP (4.1%-10.7%) across all subgroups, and median duration of response with T-DXd+P approached 3 years. Early OS data showed a positive trend favoring T-DXd+P (HR, 0.60 for PFS2), and the safety profile was consistent with the known profiles of each individual agent.¹⁰

Maintenance Therapy Strategies: PATINA and HER2CLIMB-05

Beyond induction strategies, several trials are redefining first-line maintenance. The PATINA trial (NCT02947685) evaluated the addition of palbociclib (Ibrance) to anti-HER2 therapy plus endocrine therapy as maintenance for HR+/HER2+ metastatic breast cancer following induction chemotherapy. With a median follow-up of 53.5 months, palbociclib extended investigator-assessed PFS (median 44.3 vs 29.1 months; HR, 0.74; 95% CI, 0.58-0.94; 1-sided P =.011).¹¹ While not yet approved by the European Medicines Agency in this indication, these findings support further evaluation of CDK4/6 inhibition in the HER2+ context.

The HER2CLIMB-05 trial (NCT05132582) randomized 654 patients without progression after THP induction to tucatinib or placebo, each combined with trastuzumab and pertuzumab.¹² Addition of tucatinib extended investigator-assessed PFS to 24.9 months compared with 16.3 months for placebo plus HP (HR, 0.641; 95% CI, 0.514-0.799; P <.0001), with a numerical OS trend favoring tucatinib (HR, 0.539; 95% CI, 0.303-0.957). Notable adverse events in the tucatinib arm included hepatic events (grade ≥3 in 15.3%) and diarrhea (any grade in 72.7%), with hepatic toxicity leading to treatment discontinuation in 7.7% of patients.

Additional ongoing maintenance studies include heredERA (NCT05296798; giredestrant plus pertuzumab-trastuzumab in ER+/HER2+ MBC), INAVO122 (NCT05894239; inavolisib [Itovebi] plus pertuzumab-trastuzumab in PIK3CA-mutated tumors), and DEMETHER (NCT06172127; T-DXd induction followed by pertuzumab-trastuzumab subcutaneous maintenance), each targeting distinct biological subsets and collectively aiming to individualize maintenance therapy.

The Case for Treatment Sequencing Trials With ADCs

As ADCs move into earlier lines of therapy, the design of rigorous sequencing trials becomes increasingly important. Sequencing decisions are not clinically neutral: ADCs share overlapping targets (HER2, TROP2, HER3), payloads (topoisomerase I inhibitors), and toxicity profiles, making the order of administration biologically consequential. Cross-resistance, cumulative toxicity, and high real-world attrition rates—estimated below 5% for the shift from first-line to subsequent therapy in HER2+ metastatic breast cancer—must be incorporated into trial designs.

A true sequence trial must be distinguished from a standard first-line superiority study. Sequence-type trials require prespecified decision rules for treatment switching, a primary or key secondary end point capturing outcomes beyond first progression (such as PFS2 or OS), protocol-governed access to second-line therapy, and formal assessment of cumulative toxicity and patient-reported outcomes. The SONIA trial (NCT03425838) in HR+/HER2– metastatic breast cancer provides an illustrative archetype: using a treatment-strategy estimand with PFS2 as the primary end point, it demonstrated noninferiority of deferred vs upfront CDK4/6 inhibition, informing sequencing practice without moving to a superior first-line agent.¹³

For HER2+ metastatic breast cancer specifically, the most clinically meaningful sequencing question may not be ADC vs ADC but rather upfront ADC vs chemotherapy-first followed by ADC, a strategy that may spare patients from early ADC-related toxicities while preserving second-line efficacy. Researchers should also prioritize studies designed to understand and overcome resistance mechanisms following prior ADC exposure, as post-ADC PFS with a subsequent ADC is typically limited to 2 to 3 months in unselected populations.

Conclusions

The HER2+ metastatic breast cancer landscape is at an inflection point. T-DXd+P demonstrated superior PFS over the established THP standard in the DESTINY-Breast09 trial, positioning ADC-based regimens as a potential new first-line standard. Alongside this, novel maintenance strategies with tucatinib, palbociclib, and selective estrogen receptor degraders are expanding options for disease control following induction chemotherapy. As these treatments are integrated into clinical practice, Curigliano urged that the oncology community must invest in rigorously designed sequencing and strategy trials, guided by robust estimands, protocol-governed postprogression management, and biomarker-driven patient selection, to ensure that advances in first-line efficacy translate into meaningful, durable benefit across the full treatment continuum.

DISCLOSURES: Dr Curigliano reports serving as a board member for Ellipses; consultant for Lilly, Novartis, Seattle Genetics, and Roche-Genentech; receipt of research grants to his institution from MSD and AstraZeneca; and participation in speakers bureaus for Pfizer, Lilly, Novartis, Roche-Genentech, Samsung, and Celltrion. No stock ownership was reported.

REFERENCES

1. Curigliano G. Sequencing therapy for HER2+ metastatic breast cancer. Presented at: 2026 Miami Breast Cancer Conference; March 5-8, 2026; Miami, FL.

2. Curigliano G, et al. ESMO Metastatic Breast Cancer Living Guidelines. v1.2 April 2025.

3. Swain SM, Miles D, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519-530.

4. Miles D, Ciruelos E, Schneeweiss A, et al. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncol. 2021;32(10):1245-1255.

5. Arpino G, De Laurentiis M, Ferrero JM, et al. PERTAIN study final analysis: pertuzumab plus trastuzumab and an aromatase inhibitor for HER2+/HR+ metastatic breast cancer. Clin Cancer Res. 2023;29(8):1468-1476.

6. Hurvitz SA, Hegg R, Chung WP, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03. Lancet. 2023;401(10371):105-117.

7.Cortés J, Kim SB, Chung WP, et al. Overall survival with trastuzumab deruxtecan vs trastuzumab emtansine in HER2-positive breast cancer. Nat Med. 2024;30(8):2208-2215.

8. André F, et al. DESTINY-Breast07: T-DXd monotherapy and T-DXd + pertuzumab in first-line HER2+ metastatic breast cancer. ESMO Open. 2025;10(2):104163.

9. Tolaney SM, Jiang Z, Zhang Q, et al. Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med. 2025 Oct 29.

10. Loibl S et al.LBA18 Trastuzumab deruxtecan (T-DXd) + pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for patients (pts) with HER2+ advanced/metastatic breast cancer (a/mBC): Additional analyses of DESTINY-Breast09 in key subgroups of interest. Ann Onc. Volume 36, S1563 - S1564

11. Metzger O, Mandrekar S, Goel S, et al. Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med. 2026 Jan 29;394(5):451-462.

12. Dieras V, Curigliano G, Martin M, et al. HER2CLIMB-05: A phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer. J Clin Oncol. 2025 Dec 10:JCO2502600.

13. Sonke GK, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for overall survival in patients with HR+, HER2-negative advanced breast cancer (SONIA): a randomised, phase 3 trial. Nature. 2024;636(8042):474-480.